《中国康复理论与实践》

中国康复理论与实践 >

2018 , Vol. 24 >Issue 8: 987 - 992

DOI: https://doi.org/10.3969/j.issn.1006-9771.2018.08.021

论文康复论坛

视神经脊髓炎谱系疾病的免疫治疗策略

  • 方丽波 ,
  • 刘广志 ,
  • 薛迎红
展开
  • 1.首都医科大学附属复兴医院神经内科,北京市 100038;
    2.首都医科大学附属安贞医院神经内科,北京市 100029
方丽波(1966-),女,汉族,北京市人,硕士,副主任医师,主要研究方向：脑血管病、神经系统免疫性疾病。

收稿日期: 2018-04-03

  修回日期: 2018-05-21

  网络出版日期: 2018-08-20

收起

Immunotherapy Strategies for Neuromyelitis Optica Spectrum Disorder

  • FANG Li-bo ,
  • LIU Guang-zhi ,
  • XUE Ying-hong
Expand
  • 1. Department of Neurology, Fuxing Hospital, Capital Medical University, Beijing 100038, China;
    2. Department of Neurology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China

Received date: 2018-04-03

  Revised date: 2018-05-21

  Online published: 2018-08-20

Fold

摘要

在遵循循证医学基础上,结合疾病的发病机制及药物的作用机制,本文论述了近年来国内外针对视神经脊髓炎谱系疾病(NMOSD)的急性期治疗、预防复发治疗及潜在的免疫治疗。急性期治疗以抑制炎性应答,降低水通道蛋白4 (AQP4)抗体滴度为主,主要使用大剂量激素冲击疗法、血浆置换疗法。缓解期治疗以抑制T细胞、B细胞的增殖及去除体内B细胞为主,减少复发次数,主要给予硫唑嘌呤、利妥昔单抗及吗替麦考酚酯等。未来NMOSD的治疗将更趋于靶向性/特异性,其作用机制主要通过阻断致病性AOP4抗体与其抗原的结合,减少致病性AQP4抗体生成,阻断致病性抗体-抗原结合后的下游反应;主要包括aquaporumab、托珠单抗、DNA疫苗、抗CD19单克隆抗体(MEDI-551)、艾库组单抗及贝伐单抗等。

关键词： 视神经脊髓炎谱系疾病; 水通道蛋白4; 免疫治疗

本文引用格式

方丽波 , 刘广志 , 薛迎红 . 视神经脊髓炎谱系疾病的免疫治疗策略[J]. 中国康复理论与实践, 2018 , 24(8) : 987 -992 . DOI: 10.3969/j.issn.1006-9771.2018.08.021

Abstract

This paper assembled immunotherapy methods for neuromyelitis optica spectrum disorder (NMOSD) in recent years, including the treatment of acute stage, the prevention of relapse and the potential immunotherapy. The treatment of acute stage is mainly to inhibit inflammatory response and reduce aquaporin 4 (AQP4) antibody(Ab) titer, and this is done mainly by using high-dose hormone shock therapy and plasmapheresis. Remission treatment is to inhibit the proliferation of T cells and B cells and also remove B cells from the body, for the purpose of reducing the number of relapses. Azathioprine, rituximab and mycophenolate mofetil are mainly given during remission stage. The treatment of NMOSD will become more targeted/specific in the future. The mechanism of action of the new drug is mainly through blocking the binding of pathogenic AQP4-Ab and its antigen (Ag), reducing the generation of pathogenic AQP4-Ab, and blocking the downstream reaction after pathogenic Ab-Ag binding. The new drugs mainly include aquaporumab, tocilizumab, DNA vaccine, anti-CD19 monoclonal Ab (MEDI-551), eculizumab and bevacizumab.

Key words： neuromyelitis optica spectrum disorder; aquaporin 4; immunotherapy

参考文献

[1] Lennon VA, Kryzer TJ, Pittock SJ, et al.IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel[J]. J Exp Med, 2005, 202(4): 473-477.
[2] Wingerchuk DM, Banwell B, Bennell JL, et al.International consensus diagnostic criteria for neuromyelitis optica spectrum disorders[J]. Neurology, 2015, 85(2): 177-189.
[3] 王月彩,檀国军,王程晓. 神经脊髓炎谱系疾病的治疗现状及进展[J]. 临床荟萃, 2016, 31(10): 1155-1160.
[4] Liao MF, Chang KH, Lye RK, et al.Comparison between the cranial magnetic resonance imaging features of neuromyelitis optica spectrum disorder versus multiple sclerosis in Taiwanese patients[J]. BMC Neurol, 2014, 14: 218.
[5] Wingerchuk DM, Banwel LB, Bennrtt JL, et al.International consensus diagnostic criteria for neuromyelitis optica spectrum disorders[J]. Neurology, 2015, 85(2): 177-189.
[6] Waters P, Woodhall M, O'Connor KC, et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease[J]. Neurol Neuroimmunol Neuroinflamm, 2015, 2(3): e89.
[7] Höftberger R, Sepulveda M, Armangue T, et al.Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease[J]. Multiple Sclerosis, 2015, 21(7): 866-874.
[8] Papadopoulos MC, Bennett JI, Verkman AS.Treatment of neuromyelitis optica: state-of-the-art and emerging therapies[J]. Nat Rev Neu, 2014, 10(9): 493-506.
[9] Kimbrough DJ, Fujihara K, Jacob A, et al.Treatment of neuromyelitis optica: review and recommendations[J]. Mult Scler Relat Disord, 2012, 1(4): 180-187.
[10] Torres J, Pruitt A, Balcer L, et al.Analysis of the treatment of neuromyelitis optica[J]. J Neurol Sci, 2015, 351(1-2): 29-36.
[11] Yamasaki R, Matsushita T, Fukazawa T, et al.Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica[J]. Mult Scler, 2015, 22(10): 1337-1348.
[12] 叶静. 视神经脊髓炎[M]//刘广志. 多发性硬化. 北京:北京大学医学出版社, 2012: 245-246.
[13] Kim SH, Kim W, Huh SY, et al.Clinical efficacy of plasmapheresis in patients with neuromyelitis optica spectrum disorder and effects on circulating anti-aquaporin-4 antibody levels[J]. J Clin Neurol, 2013, 9(1): 36-42.
[14] Lim YM, Pyun SY, Kang BH, et al.Factors associated with the effectiveness of plasma exchange for the treatment of NMO-IgG-positive neuromyelitis optica spectrum disorders[J]. Mult Scler, 2013, 19(9): 1216-1218.
[15] Viswanathan S, Wong AHY, Quek AML, et al.Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica[J]. J Neuroimmunol, 2015, 282: 92-96.
[16] Kleiter I, Gold R.Present and future therapies in neuromyelitis optica spectrum disorders[J]. Neurotherapeutics, 2015, 13(1): 70-83.
[17] Wei Q, Kermode AG, Rui L, et al.Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica[J]. J Clin Neuro Soci, 2015, 22(7): 1178-1182.
[18] Chen H, Zhang Y, Shi Z, et al.The efficacy and tolerability of mycophenolate mofetil in treating neuromyelitis optica and neuromyelitis optica spectrum disorder in western China[J]. Clin Neuropharmacol, 2016, 39(2): 81-87.
[19] Rommer PS, Dörner T, Freivogel K, et al.Safety and clinical outcomes of rituximab treatment in patients with multiple sclerosis and neuromyelitis optica: experience from a National Online Registry (GRAID)[J]. J Neuroimmune Pharmacol, 2015, 11(1): 1-8.
[20] Trebst C, Jarius S, Berthele A, et al.Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group(NEMOS)[J]. J Neurol, 2014, 261(1): 1-16.
[21] Yang CS, Yang L, Li T, et al.Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica[J]. Neurology, 2013, 81(8): 710-713.
[22] Kitley J, Elsone L, George J, et al.Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin -4 antibodies[J]. J Neurol Neurosurg Psychiatry, 2013, 84: 918-921.
[23] Vodopivec I, Matiello M, Prasad S.Treatment of neuromyelitis optica[J]. Curr Opin Ophthalmol, 2015, 26(6): 476-483.
[24] Palace J, Leite MI, Nairne A, et al.Interferon Beta treatment in neuromyelitis optica:increase in relapses and aquaporin 4 antibody titers[J]. Arch Neurol, 2010, 67(8): 1016-1017.
[25] Miyazaki K, Abe Y, Iwanari H, et al.Establishment of monoclonal antibodies against the extracellular domain that block binding of NMO-IgG to AQP4[J]. J Neuroimmunol, 2013, 260(1-2): 107-116.
[26] Wang H, Wang K, Wang C, et al.Cerebrospinal fluid highmobility group box protein 1 in neuromyelitis optica and multiple sclerosis[J]. Neuroimmunomodulation, 2013, 20(2): 113-118.
[27] Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, et al.Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter[J]. Ann Neurol, 2012, 72(1): 53-64.
[28] Ayzenberg I, Kleiter I, Schröder A, et al.Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy[J]. JAMA Neurol, 2013, 70(3): 394-397.
[29] Kieseier BC, Stüve O, Dehmel T, et al.Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses[J]. JAMA Neurol, 2013, 70(3): 390-393.
[30] Patrick A, Jamma L, Chris A, et al.Resolution of aquaporin-4 antibodies in a woman with neuromyelitis optica treated with human autologous stem cell transplant[J]. J Clin Neurosci, 2015, 22: 1215-1217.
[31] Pittock SJ, Lennon VA, McKcon A, et al. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study[J]. Lancet Neurol, 2013, 12(6): 554-562.
[32] Uzawa A, Mori M, Uchida T, et al.Increased levels of CSF CD59 in the long-term course of neuromyelitis optica[J]. Clin Chim Acta, 2016, 453: 131-133.
[33] Saadoun S, Waters P, MacDonald C, et al. Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain[J]. Ann Neurol, 2012, 71: 323-333.
[34] Zhang H, Verkman AS.Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica[J]. J Clin Invest, 2013, 123(5): 2306-2316.
[35] Kemp K, Redondo J, Hares K, et al.Oxidative injury in multiple sclerosis cerebellar grey matter[J]. Brain Res, 2016, 1642: 452-460.
[36] Mealy MA, Shin K, John G, et al.Bevacizumab is safe in acute relapses of neuromyelitis optica[J]. Clin Exp Neuroimmunol, 2015, 6(4): 413-418.
[37] Papadopoulos MC, Bennett JL, Verkman AS.Treatment of neuromyelitis optica: state-of-the-art and emerging therapies[J]. Nat Rev Neurol, 2014, 10(9): 493-506.
Options
文章导航

/

〈 〉